DNAtriX Secures $20,000,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3e764dc7-5c08-4f3f-b5cf-d16aa89d641a
Date
10/14/2014
Company Name
DNAtriX
Mailing Address
One Greenway Plaza Houston, TX 77046 USA
Company Description
DNAtriX, Inc. is a Texas-based biotechnology company focused on the development of an oncoloytic virus platform initially for the treatment of malignant glioma. DNAtriX’s lead product, delta24RGD, is a next-generation adenovirus invented by company founder Dr. Juan Fueyo and Dr. Frank McCormick.
Website
http://www.dnatrix.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series B
Proceeds Purposes
Securing this funding is a significant milestone that will enable us to advance our lead oncolytic virus product, DNX-2401, into late stage clinical trials for glioblastoma.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor